References
1. Structures of concanamycins B and C: H. Kinashi, et al.; J. Antibiot. 35: 1618 (1982). 2. Isolation and characterization of concanamycins A, B and C: H. Kinashi, et al.; J. Antibiot. (Tokyo) 37: 1333 (1984). 3. Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells: M. Yilla, et al.; J. Biol. Chem. 268: 19092 (1993). 4. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosintriphosphatase: S. Drose, et al.; Biochemistry 32: 3902 (1993). 5. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells: F.J. Sharom, et al.; Biochem. J. 308 (Pt2): 381 (1995). 6. Concanamycin B inhibits the expression of newly synthesized MHC class II molecules on the cell surface: K. Ito, et al.; J. Antibiot. 48: 488 (1995) 7. Concanamycin B, a vacuolar H(+)-ATPase specific inhibitor suppresses bone resorption in vitro: J.T. Woo, et al.; Biol. Pharm. Bull. 19: 297 (1996). 8. In vivo rapid reduction of alloantigen-activated CD8+ mature cytotoxic T cells by inhibitors of acidification of intracellular organelles, prodigiosin 25-C and concanamycin B: M. H. Lee, et al.; Immunology 99: 243 (2000). 9. Y. Sasazawa, et. al.; Cancer Sci. 100: 1460 (2009). 10. Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory- pathway proteins: J. A. Sobota, et. al.; J. Cell Sci. 122: 3542 (2009) 11. Inhibitors of V-ATPase: old and new players: M. Huss, et. al.; J. Exp. Biol. 212: 341 (2009)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
